F3 Antibody

What is the F3 protein and why is it significant in research?

F3, also known as Tissue Factor or Coagulation Factor III (CD142), is a transmembrane glycoprotein that initiates the blood coagulation cascade by functioning as a high-affinity receptor for coagulation factor VII. Beyond hemostasis, F3 plays critical roles in angiogenesis, inflammation, and cell survival pathways. Research has demonstrated its significant implications in various pathologies including thrombotic disorders and cancer . The protein consists of an extracellular domain, a transmembrane region, and a cytoplasmic tail. Mouse F3, for example, is synthesized as a 294 amino acid precursor with a signal peptide (residues 1-28) and the mature chain (residues 29-294), containing a transmembrane region (residues 252-274) and a cytoplasmic tail (residues 275-294) .

What are the major types of F3 antibodies available for research?

F3 antibodies are available in several formats and technologies:

Recombinant F3 antibodies offer several advantages over traditional monoclonal antibodies, including increased sensitivity, confirmed specificity, high repeatability, excellent batch-to-batch consistency, sustainable supply, and animal-free production .

How should researchers optimize F3 antibody usage in Western blot experiments?

For Western blot applications, the protocol should be carefully optimized based on the specific F3 antibody being used. Based on published protocols:

• Sample preparation: Load human F3 protein in reduced conditions (0.1-0.6 μg protein range)

• Gel separation: Use 12% Tris-HCl polyacrylamide gels

• Transfer: Transfer proteins to CN membrane

• Blocking: Block with 5% skim milk for at least one hour

• Primary antibody incubation: Use 2 μg/mL concentration for optimal signal

• Secondary antibody: HRP-conjugated species-specific IgG at 1:5000 dilution

• Detection: Use chemiluminescent detection methods

This approach has been documented to yield clear, specific bands for F3 detection . For recombinant F3 antibodies like CSB-RA776663A0HU, dilutions ranging from 1:500-1:5000 are recommended for Western blot applications .

What are the best practices for immunoprecipitation with F3 antibodies?

Immunoprecipitation with F3 antibodies requires:

• Lysate preparation: Use cell types known to express F3 (monocytes, endothelial cells) or induce expression with LPS in appropriate cell lines (e.g., RAW 264.7)

• Pre-clearing: Remove non-specific binding proteins with protein A/G beads

• Antibody incubation: Use 2-5 μg of purified F3 antibody per 500 μg of total protein

• Bead capture: Incubate with protein A/G beads for 2-4 hours

• Washing: Use stringent wash buffers to minimize non-specific binding

• Elution: Use either acidic conditions or SDS-PAGE sample buffer

• Analysis: Western blot confirmation with a different F3 antibody clone

This approach minimizes non-specific interactions while maximizing target recovery .

How can biolayer interferometry be used to determine F3 antibody binding characteristics?

Biolayer interferometry (BLI) provides quantitative binding kinetics for F3 antibodies:

• Capture F3 antibody on appropriate sensors (e.g., anti-mouse IgG Fc for mouse-derived antibodies)

• Establish baseline in buffer

• Associate with varying concentrations of F3 antigen (typically 0.1-100 nM range)

• Dissociate in buffer

• Calculate association rate (kon), dissociation rate (koff), and equilibrium dissociation constant (KD)

Examples from published data show high-affinity binding for many F3 antibodies, with KD values in the picomolar to low nanomolar range. The F3 and F23 antibodies showed KD values of approximately 1 pM, while F19 showed a KD of 0.165 nM . Maximum biolayer thicknesses varied between antibodies (F3: 0.4 nm; F19 and F23: 0.6 nm), suggesting differences in antigen capture capacity .

How do researchers determine epitope specificity of F3 antibodies?

Epitope determination for F3 antibodies involves multiple complementary approaches:

• Peptide mapping: Testing antibody binding to synthesized peptides covering the full F3 sequence

  • Note: Some conformational epitopes may not be detected by this method, as seen with F3, F19, and F23 antibodies that did not bind to linear peptides

• Competition assays: Testing whether unlabeled antibodies block binding of labeled antibodies

  • Example data: F3-HRP binding to F1 antigen was almost completely blocked by F19 and F23, with >70% inhibition, suggesting similar binding sites

• Deletion/mutation analysis: Using truncated or mutated F3 proteins to narrow down binding regions

• Cross-reactivity analysis: Testing binding to F3 from different species to identify conserved epitopes

  • Human Tissue Factor shares 57.6% and 57.2% amino acid sequence identity with mouse and rat Tissue Factor, respectively

• Hydrogen-deuterium exchange mass spectrometry: For precise mapping of conformational epitopes

These comprehensive approaches enable researchers to distinguish between antibodies targeting different epitopes, which is crucial for selecting appropriate antibodies for specific applications .

What considerations should be made when using F3 antibodies in flow cytometry experiments?

Flow cytometry with F3 antibodies requires special consideration:

• Cell preparation: Use gentle enzymatic dissociation to preserve membrane epitopes

• Fixation protocol: Optimize to maintain epitope accessibility (e.g., 1-4% paraformaldehyde)

• Blocking strategy: Use species-appropriate serum (5-10%) to reduce non-specific binding

• Titration: Determine optimal antibody concentration (typically 1-10 μg/mL)

• Controls: Include isotype controls matched to primary antibody subclass

• Gating strategy: Account for potential heterogeneity in F3 expression levels

Published protocols have demonstrated successful detection of F3 on LPS-stimulated RAW 264.7 cells using 2.5 μg of antibody per 10^6 cells, followed by PE-conjugated secondary antibodies . This approach allows quantification of F3 expression levels across different cell populations.

How can researchers apply F3 antibodies to study disease mechanisms?

F3 antibodies have proven valuable in elucidating disease mechanisms through multiple applications:

• Cancer research: F3 is implicated in tumor progression

  • F3 expression is higher in glioblastoma (GBM) than in IDH-mutant glioma, and F3 antibody-drug conjugates (tisotumab vedotin) show greater efficacy against GBM cells

• Thrombosis models: F3 initiates coagulation

  • F3 antibodies can be used to assess tissue factor activity in various vascular disorders and thrombotic conditions

• Inflammatory conditions: F3 contributes to inflammation

  • SENP3 in monocytes/macrophages up-regulates tissue factor and mediates LPS-induced acute lung injury by enhancing JNK phosphorylation

• Hypoxia research: F3 is regulated by oxygen levels

  • Hypoxia-induced up-regulation of tissue factor is mediated through extracellular RNA activated Toll-like receptor 3-activated protein 1 signaling

• Adipocyte biology: F3 expression in adipose tissue

  • Adipocytes express tissue factor and FVII and are procoagulant in a TF/FVIIa-dependent manner

These applications demonstrate how F3 antibodies serve as critical tools for mechanistic studies across diverse pathologies.

How can researchers validate the specificity of F3 antibodies?

Validating F3 antibody specificity requires a multi-pronged approach:

• Positive and negative control tissues/cells:

  • Positive: Known F3-expressing tissues (placenta, kidney, CNS)

  • Negative: Tissues/cells with minimal F3 expression

• Knockout/knockdown validation:

  • Test antibody in F3 knockout or siRNA-mediated knockdown samples

  • Absence of signal confirms specificity

• Peptide competition:

  • Pre-incubate antibody with immunizing peptide

  • Loss of signal indicates specific binding

• Western blot molecular weight verification:

  • Human F3 should appear at approximately 47 kDa (glycosylated)

  • Mouse F3 shows a band at approximately 15.5 kDa in its unmodified form

• Cross-reactivity assessment:

  • Test against related family members

  • Evaluate binding to F3 from different species

Rigorous validation ensures experimental reliability and reproducibility when working with F3 antibodies.

What factors most commonly affect F3 antibody performance, and how can they be mitigated?

Several factors can impact F3 antibody performance:

Recognizing these potential issues enables researchers to implement appropriate controls and optimization strategies to ensure consistent, reliable results.

How should researchers interpret binding affinity data for F3 antibodies?

Interpreting binding affinity data requires consideration of multiple parameters:

• KD (equilibrium dissociation constant):

  • Lower values indicate stronger binding

  • F3 antibodies with picomolar KD values (e.g., F3, F23 at ~1 pM) demonstrate extremely high affinity

  • Antibodies with nanomolar KD values (e.g., F19 at 0.165 nM) still show strong binding

• Association rate (kon):

  • Higher values indicate faster binding

  • Important for applications like immunoprecipitation

• Dissociation rate (koff):

  • Lower values indicate more stable binding

  • Critical for applications requiring wash steps

• Biolayer thickness:

  • Indicates amount of antigen captured

  • F3 antibody showed 0.4 nm thickness while F19 and F23 showed ~0.6 nm

• EC50 values from ELISA:

  • F3, F19, and F23 showed EC50 values of 6.92 ng/mL, 19.4 ng/mL, and 11.36 ng/mL respectively

  • Lower values indicate higher sensitivity

Comparing these parameters across different antibodies helps researchers select the most appropriate reagent for specific applications and interpret experimental results accurately.

How are F3 antibodies being developed for therapeutic applications?

F3 antibodies are being explored for several therapeutic applications:

• Antibody-drug conjugates (ADCs):

  • Tisotumab vedotin (a TF antibody conjugated to monomethyl auristatin E) targets cancers with high TF levels

  • Preclinical data show effectiveness against glioblastoma, though with side effects including intra/peritumoral hemorrhage

• Anticoagulant therapy:

  • F3 antibodies can inhibit the initiation of coagulation

  • Potential applications in thrombotic disorders

• Cancer immunotherapy:

  • F3 antibodies could be used to target tumor-associated tissue factor

  • May be combined with immune checkpoint inhibitors

• Anti-inflammatory applications:

  • F3 antibodies like F3-2 have shown ability to prevent trypsin cleavage and inhibit virus infection

These therapeutic developments highlight the translational potential of F3 antibody research beyond basic science applications.

What technological innovations are improving F3 antibody development and characterization?

Recent technological advances enhancing F3 antibody research include:

• Massively parallel screening:

  • Illumina HiSeq platform enables screening of ~10^8 antibody-antigen interactions within 3 days

  • Accelerates high-affinity antibody discovery from months to 2-3 days

• Machine learning approaches:

  • Deep-screening datasets serve as input for ML models trained on antibody-antigen interactions

  • Enables rapid generation of new high-affinity antibody sequences

• Recombinant antibody technologies:

  • F3 recombinant monoclonal antibody synthesis involves protein technology and DNA recombinant technology

  • Mice are immunized, spleen RNA is extracted, cDNA is synthesized, and the F3 antibody gene is amplified via PCR

  • The gene is introduced into a vector, transfected into host cells, and the antibody is purified from cell culture supernatant using affinity chromatography

• High-throughput epitope mapping:

  • Peptide arrays and hydrogen-deuterium exchange mass spectrometry enable rapid epitope identification

  • Competition assays with labeled and unlabeled antibodies help determine epitope relationships

These innovations are accelerating F3 antibody development while improving antibody quality and performance characteristics.